Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478551 · ClinicalTrials.gov registry record · Phase 2
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
A Phase 2 study of Scar and Hypertrophic Scar, sponsored by Henry Ford Health System.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05478551 is a Phase 2 study of Scar and Hypertrophic Scar that is active but no longer recruiting, run by Henry Ford Health System. The registered enrollment target is 12 participants, below the 48-participant average among 15 other Scar trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05478551, a Phase 2 study of Scar and Hypertrophic Scar, is active but no longer recruiting, sponsored by Henry Ford Health System.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Botulinum Toxin
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478551
The ClinicalTrials.gov registry entry for NCT05478551 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 15 other Scar trials with a reported enrollment target (75% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Scar appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT05478551 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05478551 about?
NCT05478551 is a clinical study titled "Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization". The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We...
What is the current status of trial NCT05478551?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-06-01. Estimated completion is 2026-12-30.
What conditions does trial NCT05478551 study?
This clinical trial studies the following conditions: Scar, Hypertrophic Scar.
What interventions are being tested in trial NCT05478551?
The interventions under investigation include: Normal saline (DRUG), Botulinum Toxin (DRUG).
Who is sponsoring clinical trial NCT05478551?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05478551 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Regimen Study of SLI-F06 in Healthy Volunteers
RECRUITING · Phase 2
-
A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
COMPLETED · Phase 2
-
Microneedling vs Dermabrasion for Early Facial Scar Resurfacing
RECRUITING · NA
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Paraffin Wax and Exercise Prospective
RECRUITING · NA
-
Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.